Teladoc Health (NYSE:TDOC) PT Lowered to $21.00

Teladoc Health (NYSE:TDOC) had its price objective reduced by Oppenheimer from $26.00 to $21.00 in a research report sent to investors on Friday, Benzinga reports. Oppenheimer currently has an outperform rating on the health services provider’s stock.

Other research analysts also recently issued research reports about the stock. Truist Financial decreased their price objective on shares of Teladoc Health from $23.00 to $17.00 and set a hold rating for the company in a research report on Wednesday, March 6th. Citigroup lowered their price target on Teladoc Health from $21.00 to $19.00 and set a neutral rating on the stock in a research report on Wednesday, February 21st. Evercore ISI dropped their price objective on Teladoc Health from $15.00 to $14.00 and set an in-line rating on the stock in a research note on Friday. Canaccord Genuity Group reduced their target price on Teladoc Health from $28.00 to $25.00 and set a buy rating for the company in a research note on Friday. Finally, Leerink Partnrs restated a market perform rating on shares of Teladoc Health in a research note on Monday, February 26th. Twelve investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of Hold and an average price target of $18.73.

Teladoc Health Trading Up 3.0 %

NYSE:TDOC opened at $13.40 on Friday. The company has a market cap of $2.27 billion, a P/E ratio of -9.50 and a beta of 0.94. Teladoc Health has a twelve month low of $12.65 and a twelve month high of $30.41. The business has a 50 day moving average price of $14.69 and a two-hundred day moving average price of $17.67. The company has a quick ratio of 3.47, a current ratio of 3.54 and a debt-to-equity ratio of 0.66.

Teladoc Health (NYSE:TDOC) last released its earnings results on Thursday, April 25th. The health services provider reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.02). Teladoc Health had a negative net margin of 8.90% and a negative return on equity of 10.11%. The company had revenue of $646.13 million during the quarter, compared to analyst estimates of $637.31 million. During the same period in the prior year, the firm posted ($0.37) EPS. Teladoc Health’s revenue was up 2.7% compared to the same quarter last year. As a group, analysts expect that Teladoc Health will post -1.06 EPS for the current fiscal year.

Insider Transactions at Teladoc Health

In related news, insider Laizer Kornwasser sold 7,882 shares of Teladoc Health stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $19.18, for a total transaction of $151,176.76. Following the sale, the insider now directly owns 57,223 shares of the company’s stock, valued at approximately $1,097,537.14. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Teladoc Health news, insider Arnnon Geshuri sold 7,500 shares of the business’s stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $15.06, for a total transaction of $112,950.00. Following the sale, the insider now directly owns 38,470 shares of the company’s stock, valued at approximately $579,358.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Laizer Kornwasser sold 7,882 shares of the firm’s stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $19.18, for a total transaction of $151,176.76. Following the transaction, the insider now directly owns 57,223 shares of the company’s stock, valued at approximately $1,097,537.14. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 135,441 shares of company stock valued at $2,038,251. 1.63% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Teladoc Health

Several institutional investors and hedge funds have recently made changes to their positions in the stock. ICA Group Wealth Management LLC bought a new stake in Teladoc Health in the fourth quarter valued at approximately $28,000. Hexagon Capital Partners LLC boosted its stake in shares of Teladoc Health by 204.4% in the 4th quarter. Hexagon Capital Partners LLC now owns 1,586 shares of the health services provider’s stock valued at $34,000 after purchasing an additional 1,065 shares during the last quarter. RIA Advisory Group LLC acquired a new stake in shares of Teladoc Health during the fourth quarter worth $36,000. GAMMA Investing LLC bought a new position in Teladoc Health during the fourth quarter worth $41,000. Finally, Principal Securities Inc. acquired a new position in Teladoc Health in the fourth quarter valued at $45,000. Institutional investors and hedge funds own 76.82% of the company’s stock.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.